# **Introduction to MiDatabank Version 3**

MiDatabank Version 3 is a major new release that has many new features. The following is a brief summary that introduces some of these features.

## **New Features for the Pharmaceutical Industry:**

- Recording of Product-related MI Enquiries
- Recording of Product-related Complaints for transfer to QA Department
- Recording of Product-related Adverse Drug Reactions
  - o Facility to transfer ADR data to Pharmacovigilence Department
  - Facility to electronically transmit ADR data (e.g. Yellow Card in the UK) to Regulatory Authority

# **New Features for Hospitals:**

- Streamline the recording of enquiries
- Broadening the scope to be a core tool in Hospital Pharmacy
- Enable Clinical Pharmacists to record enquiries
- Supporting Pharmacists with their Professional Development
- Electronically transmit ADR data (e.g. Yellow Card in the UK) to Regulatory Authority

#### MiDatabank Document Types


MiDatabank can create, edit and manage the following types of document


- Enquiries
  - Medicines Information Enquiries
  - o ADR Enquiries
  - Complaints
- FAQs Frequently Asked Question
- Projects Documentation of Formulary decisions, Horizon Scanning etc


#### **Medicines Information (MI) Enquiries**


MiDatabank has an established mechanism to record a MI type of enquiry. This involves documenting the process of taking data input, performing research and transfer of the answer to the enquirer.


With version 3 of MiDatabank, there are a number of new facilities:













The new facilities are configurable in the MiDatabank Administration module. For example, the screen-shot show below shows an additional category 'Possible Q & A' has been added to the standard set of categories.

In addition, note that there are 'Over-ride' buttons that enable the text displayed in the Helper Panel, and the Standard Search Pattern to be customised according to needs of the centre.



## **Adverse Drug Reactions (ADR) Enquiries**

MiDatabank version has introduced a mechanism for capturing all the required information for reporting an ADR to the Regulatory Authority. In the UK this consists of submitting a Yellow Card to the MHRA



The industrial version of MiDatabank also has this facility as an alternative to passing the ADR to their Pharmacovigilence department.

The report shown below is an example report that might be submitted by MiDatabank to the MHRA in the UK. The data is electronically sent over the internet and is a direct database to database connection that makes the process quick, easy and efficient.

# MiDatabank Sample ADR Report

# YellowCard \*



# Helping to make medicines safer

# Suspected Adverse Drug Reactions In Confidence

MiDatabank User Name: Sam Smith User Guid:0e1bdacf-a529-40c0-99cb-7d094cd0e0ce MI Centre:Demonstration Site

Reporter:

Mr Sam Smith Manager Demonstration Site CoAcS Avon Email: dfsf

Title:

Local ID: 220

Global ID: 3395e8d2-0f7d-4911-a600-802fb3f2c192

#### **Adverse Event**

Serious: False

Fatal: False Life Threatening: False Hospitalisation: False

Significant Disability False
Congenital Anomally False
Other Medical Event: False

#### **Patient Details**

Local Patient ID: 3395e8d2-0f7d-4911-a600-802fb3f2c192

Age: 56 Years on 29/01/2010

Sex: Male

#### **Patient Medication**

#### Suspected Drug(s)

Atorvastatin 40mg tablets>Lipitor 40mg tablets

SUSPECT DRUG

Action Taken:Dose reduced

Expiry: 01/01/2012

Batch: Dose: Route: Oral

Start Date: 03/12/2009 End Date: <None> Prescribed For:

Notes:

#### **Concomitant Drug(s)**

Aspirin 500mg / Codeine 8mg dispersible tablets sugar free

CONCOMITANT DRUG Expiry: 01/01/2012

Batch: Dose:

Start Date: <None> End Date: <None> Prescribed For:

Notes:

#### **Adverse Event Details**

The patient has reported intense migraine and a sudden rash of septic spots.

#### **Reporter Comments**

This is not a real ADR and is shown for demonstration purposes only.

#### Reactions

Reaction: Septic spots

Outcome: Recovered/Resolved

Start Date: 03/12/2009 End Date: <None>

Treatment: <none specified>

End of Adverse Event